anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to develop and investigate novel and established MR (magnetic resonance) imaging sequences as predictive and prognostic radiotherapy biomarkers. Radiotherapy is a fundamental treatment modality for Head and Neck Squamous Cell Carcinoma (HNSCC) with a majority of patients receiving radiation as part of their care pathway. Although treatment is effective, there remains a risk of failure particularly in those presenting with locally advanced disease. In addition, significant proportion of patients receiving radiotherapy will suffer long-term side effects related to their treatment. The addition of concurrent chemotherapy improves the efficacy of radiotherapy, but at the cost of increased treatment related toxicity. The treatment related toxicity and risk of treatment failure means there is a compelling clinical need to personalize therapy based on a patient's early response to radiotherapy.
ALT or AST >3xULN were observed in 11% of bosentan-treated patients (n=658) compared to 2% of placebo-treated patients (n=280). Three-fold increases were seen in 12% of 95 pulmonary arterial hypertension (PAH) patients on 125 mg twice daily and 14% of 70 PAH patients on 250 mg twice daily. Eight-fold increases were seen in 2% of PAH patients on 125 mg twice daily and 7% of PAH patients on 250 mg twice daily. Bilirubin increases to ≥3xULN were associated with aminotransferase increases in 2 of 658 (0.3%) of patients treated with bosentan. In a pooled analysis of four pediatric studies conducted in PAH (n =100), elevations in liver aminotransferases ≥3×ULN were observed in 2% of patients. The combination of hepatocellular injury (increases in aminotransferases of >3xULN) and increases in total bilirubin (≥2xULN) is a marker for potential serious hepatotoxicity.

Elevations of AST or ALT associated with bosentan are dose-dependent, occur both early and late in treatment, usually progress slowly, are typically asymptomatic, and usually have been reversible after treatment interruption or cessation. Aminotransferase elevations also may reverse spontaneously while continuing treatment with bosentan.

Liver aminotransferase levels must be measured prior to initiation of treatment and then monthly and therapy adjusted accordingly [see Dosage and Administration (2.1, 2.4)]. Discontinue bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥2xULN.

Avoid initiation of bosentan in patients with elevated aminotransferases (>3xULN) prior to drug initiation because monitoring hepatotoxicity in these patients may be more difficult [see Boxed Warning, Dosage and Administration (2.6), Use in Specific Populations (8.6)].

In WHO Functional Class II patients, consider whether the benefits of bosentan are sufficient to offset the risk of hepatotoxicity, which may preclude future use as their disease progresses.
New mixtures of pesticides are being placed on the market to increase the spectrum of phytosanitary action. Thus, the eco(geno)toxic effects of the new commercial mixture named Platinum Neo, as well as its constituents the neonicotinoid Thiamethoxam and the pyrethroid Lambda-Cyhalothrin, were investigated using the species Daphnia magna, Raphidocelis subcapitata, Danio rerio, and Allium cepa L. The lowest- and no-observed effect concentration (LOEC and NOEC) were measured in ecotoxicological tests. While Thiamethoxam was ecotoxic at ppm level, Lambda-Cyhalothrin and Platinum Neo formulation were ecotoxic at ppb level. The mitotic index (MI), chromosomal aberrations and micronucleus [MN] frequency were measured as indicators of phytogenotoxicity in A. cepa plants exposed for 12 h to the different insecticides and their mixture under different dilutions. There were significant alterations in the MI and MN frequency in comparison with the A. cepa negative control group, with Thiamethoxam, Lambda-Cyhalothrin, and Platinum Neo treatments all significantly reducing MI and increasing MN frequency. Thus, MI reduction was found at 13.7 mg L-1 for Thiamethoxam, 0.8 μg L-1 for Lambda-Cyahalothrin, and 2.7:2 μg L-1 for Platinum Neo, while MN induction was not observed at 14 mg L-1 for Thiamethoxam, 0.8 μg L-1 for Lambda-Cyahalothrin, and 1.4:1 μg L-1 for Platinum Neo. The insecticide eco(geno)toxicity hierarchy was Platinun Neo > Lambda-Cyhalothrin > Thiamethoxam, and the organism sensitivity hierarchy was daphnids > fish > algae > A. cepa. Eco(geno)toxicity studies of new pesticide mixtures can be useful for management, risk assessment, and avoiding impacts of these products on living beings.
SAMD9 and SAMD9L are two interferon-regulated genes located adjacent to each other on chromosome 7q21.2. Germline gain-of-function (GL GOF) mutations in SAMD9/SAMD9L are the genetic cause of MIRAGE syndrome, ataxia-pancytopenia (ATXPC) syndrome, myeloid leukemia syndrome with monosomy 7 (MLSM7), refractory cytopenia of childhood (RCC), transient monosomy 7 in children, SAMD9L-associated autoinflammatory disease (SAAD), and a proportion of inherited aplastic anemia and bone marrow failure syndromes. The myeloid neoplasms associated with GL GOF SAMD9/SAMD9L mutations have been included in the World Health Organization (WHO) 2022 classification. The discovery of SAMD9/SAMD9L-related diseases has revealed some interesting pathobiological mechanisms, such as a high rate of primary somatic compensation, with one of the mechanisms being (transient) monosomy 7 a mechanism also described as "adaption by aneuploidy." The somatic compensation in the blood can complicate the diagnosis of SAMD9/SAMD9L-related disease when relying on hematopoietic tissues for diagnosis. Recently, GL loss-of function (LOF) mutations have been identified in older individuals with myeloid malignancies in accordance with a mouse model of SAMD9L loss that develops a myelodysplastic syndrome (MDS)-like disease late in life. The discovery of SAMD9/SAMD9L-associated syndromes has resulted in a deeper understanding of the genetics and biology of diseases/syndromes that were previously oblivious and thought to be unrelated to each other. Besides giving an overview of the literature, this review wants to also provide some practical guidance for the classification of SAMD9/SAMD9L variants that is complicated by the nonrecurrent nature of these mutations but also by the fact that both GL GOF, as well as loss-of-function mutations, have been identified.
Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
INTRODUCTION: The popular traditional Chinese medicine (TCM) compound FYTF-919 (Zhong Feng Xing Nao prescription) may improve outcome from acute intracerebral hemorrhage (ICH) through effects on brain edema, hematoma absorption, and the immune system. This study is to assess whether FYTF-919 is safe and effective as compared to matching placebo treatment in patients with acute ICH.
METHODS: The ongoing Chinese Herbal medicine in patients with Acute INtracerebral hemorrhage (CHAIN) is a multicenter, prospective, randomized, double-blind placebo-controlled trial of FYTF-919 in patients with acute ICH at 20-30 hospital sites in China. Eligible ICH patients presenting within 48 h after symptom onset are randomly allocated to receive either FYTF-919 (100 mL per day × 28 d, oral) or matching placebo. A sample size of 1,504 patients is estimated to provide 90% power (α 0.05) to detect a ≥20% improvement in average utility-weight scores on the modified Rankin scale (UW-mRS) assessed at 90 days, with 6% non-adherence and 10% lost to follow-up. The primary efficacy outcome is UW-mRS at 90 days. Secondary outcomes include binary measures of the mRS, neurological impairment on the National Institute of Health Stroke Scale, and health-related quality of life on the EuroQol EQ-5D-5L scale at different time points over 6 months of follow-up. The key safety measure is serious adverse events.
CONCLUSION: CHAIN is on schedule to provide reliable evidence over the benefits of a popular herbal TCM for the treatment of acute ICH.
PROBLEM TO BE SOLVED: To obtain a gray hair inhibitor excellent in effectiveness and safety by formulating a specific benzophenone derivative as an active ingredient. SOLUTION: This inhibitor contains a benzophenone derivative of formula I [R<1> is a bonding group of the formula: O-R<2> -O-G (R<2> is an alkylene and the like; G is H, a saccharide residue, etc.) as an active ingredient. The compound of formula I is obtained by preparing a benzophenone derivative of formula III (R<3> is a bonding group of the formula: O-R<2> -OH) by etherification from 2,4-dihydroxybenzophenone of formula II and then, for example, canying out various reactions (e.g. Koenigs-Knorr reaction and the like) used for glucosylation. It is preferable that the above-stated benzophenone derivative of formula I is formulated in an amount of 0.001-20.0 wt.% based on the whole gray hair inhibitor.
Erythromycin is produced by a strain of Streptomyces erythraeusand belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. 

Erythromycin lactobionate for injection, USP is a soluble salt of erythromycin suitable for intravenous administration. The lactobionic acid content is 244 mg per vial. Lactobionic acid and/or erythromycin are used to adjust the pH during the manufacture of the product. When reconstituted as directed, each mL contains 50 mg of erythromycin activity. The pH of the reconstituted solution is 6.5 -7.5.

Erythromycin lactobionate is chemically known as erythromycin mono (4-0-β-Dgalactopyranosyl-D-gluconate) (salt). The structural formula is:
The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A  sequence to improve it as a scaffold; preferably the Stefin A comprises a heterologous peptide insertion at the Leu 73 site. Furthermore, preferably the scaffold protein comprises a V48D mutation; preferably the scaffold protein comprises a G4W mutation. Preferably the scaffold comprises Leu73, V48D and G4W mutations. The invention also relates to the scaffold proteins themselves, in particular a stefin A polypeptide having the Leu73, V48D and G4W mutations, such as shown as SEQ ID NO: 1. The invention also relates to a method for identifying binding proteins and to peptide A (RLNKPLPSLPV) and its use in treating yeast infections.
PURPOSE: Variations in the anatomy of pulmonary veins can influence selection of approaches of atrial fibrillation catheter ablation. Therefore, preprocedural evaluation and knowledge of pulmonary veins anatomy is crucial for proper mapping and the successful ablation of atrial fibrillation. The aim of this observational study was to assess CT angiography scans and perform detailed analysis of pulmonary veins morphology in patients scheduled for catheter ablation of atrial fibrillation.
METHODS: CT angiography was performed in 771 individuals (223 females, 548 males, mean age 58.4 ± 10.7 years). Pulmonary veins anatomy was evaluated using 3D models. The patterns used for evaluation included typical anatomy with four separate pulmonary veins, a common left ostium, and various types of accessory veins either alone or in combination with common left ostia.
RESULTS: An anatomical variant with common left ostium was observed as the most prevalent anatomy (44%). The typical variant was observed in 34.8% of patients. Accessory pulmonary veins were observed predominantly on the right side. The prevalence of anatomical variants did not differ between sexes with the exception of the unclassifiable category U (4.4% vs. 9%, p < 0.05).
CONCLUSIONS: Our study shows that a considerable number of atypical anatomies is present in patients undergoing AF catheter ablation. This knowledge may influence the choice of instrumentation. The data could be possibly helpful also in development of new ablation techniques.
Optimising treatment outcomes for people living with hepatitis B virus (HBV) is key to advancing progress towards international targets for the elimination of viral hepatitis as a public health threat. Nucleos/tide analogue agents (most commonly tenofovir or entecavir) are well-tolerated and suppress viraemia effectively in the majority of those who are offered therapy. However, outcomes are not consistent, and we explore the factors that may contribute to incomplete therapeutic responses. We discuss situations in which therapy is not accessible, affordable or acceptable, reflecting the impact of social, cultural and economic barriers, stigma and discrimination, low awareness, poor access to health systems and comorbidity. These challenges are amplified in certain vulnerable populations, increasing the risk of adverse outcomes-which include liver cirrhosis and hepatocellular carcinoma-among people who already experience marginalisation and health inequities. We also tackle the physiological and biological mechanisms for incomplete virological suppression in individuals receiving HBV treatment, considering the possible impact of inadequate tissue drug levels, poor drug-target avidity and genomic resistance. These factors are interdependent, leading to a complex landscape in which socioeconomic challenges increase the challenge of consistent daily therapy and set the scene for selection of drug resistance. By putting a spotlight on this neglected topic, we aim to raise awareness, prompt dialogue, inform research and advocate for enhanced interventions. As criteria for HBV treatment eligibility relax, the population receiving therapy will expand, and there is a pressing need to optimise outcomes and close the equity gap.
Research significance:The first part is the elevation of maxillary sinus floor through minimally invasive window side wall small window. Through retrospective study of implant retention rate, complications, patient subjective perception, anatomical factors and other indicators, it is used to comprehensively evaluate the clinical efficacy of this surgical procedure. In the second part, representative bone columns are taken for Micro CT scanning to evaluate the osseointegration from a histological perspective. Mimics software performs three-dimensional scanning of the transplant area, and the ratio of the window area to the volume of the transplant part is used as the main measurement index to demonstrate that minimally invasive window opening can achieve ideal bone grafting effects. Further verify the success or failure of minimally invasive side wall fenestration surgery. At present, relevant studies use this ratio as the main research data, and there is no use of 3D scanning to study changes in bone transplant areas. There are also few studies evaluating the binding of bone tissue using Micro CT, and most of them use CBCT 2D measurement data for evaluation.
Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
The invention discloses an intelligent paper diaper health analysis system and method. The system comprises the paper diaper, a health analysis device, a cloud server, a medical terminal and a mobile phone client. The health analysis device is attached to the paper diaper and comprises a detection module, a control module, a wireless transmission module and a Bluetooth transmission module. The control module is respectively connected with the detection module, the wireless transmission module and the Bluetooth transmission module through data lines, the Bluetooth transmission module is connected with the Bluetooth of the mobile phone client, and the wireless transmission module is in communication connection with the cloud server. The cloud server comprises a cloud database and an artificial intelligent diagnosis system, and the medical terminal is in communication connection with the cloud server and used for doctor diagnosis. The method comprises the following steps: urine detection, data transmission, artificial intelligence diagnosis, doctor diagnosis and result feedback. The invention increases the health detection function of the diaper, combines artificial intelligent diagnosis and doctor diagnosis, and is beneficial to the accuracy of diagnosis results and the science and reasonability of diagnosis and treatment schemes.
Objective The objective of the present study was to determine whether a preparation made from  Emblica officinalis  (Nelli/Amla) and  Tinospora cordifolia  (Rasakinda/ Guduchi) has a prognostic effect in the treatment of oral cancer. Method This study was a randomized double blind prospective clinical trial conducted at Maxillofacial Unit, Teaching Hospital, Karapitiya, Galle during the period of 2005 to 2014. The study group comprised 114 consecutive patients with oral squamous cell carcinoma (OSCC) who had attended Maxillofacial unit, Teaching Hospital, Karapitiya, Galle. Of this 70 had carcinoma in the Buccal mucosa and 44 in the Tongue. After conventional treatment of these patients, they were randomly assigned to the Trial group of 51 and Control group of 63. The Trial group was given a herbal treatment consisting of  Emblica officinalis  (Nelli) and  Tinospora iicordifolia  (Rasakinda) in powdered form. The Control was given a placebo (Viva milk powder) instead. Efficacy of herbal regime to improve the prognosis of oral carcinoma was determined by recurrence free survival and incidence of recurrence. These values in relation to age, gender and stage of the lesions were compared using SPSS soft ware and chi square statistical method. Results According to the results, both OSCC Buccal mucosa and Tongue trial groups gave better prognosis. The study managed to demonstrate that local recurrences and gross recurrence of OSCC Buccal mucosa were greatly reduced in the trial group, with trial group showing statistically significant (p = 0.02) for local recurrence and (p = 0.05) for gross recurrence. Similarly, in the trial group of OSCC Tongue, there was a remarkable reduction of nodal recurrence and gross recurrences. This was highly statistically significant for nodal recurrence (p = 0.1) and for gross recurrence (p = 0.1). In the OSCC Tongue trial group there was a greater reduction of nodal recurrences whereas a greater reduction of local recurrence observed in the OSCC Buccal mucosa trial group. The reduction of recurrences in trial groups of carcinoma of buccal mucosa and carcinoma of tongue led to better survival rates. Five-year recurrence-free survival of the trial groups of both carcinoma together, was 62.7% compared to 42.3% in the control group (p = 0.031) and statistically significant. iii Conclusion It is justifiable to conclude that the herbs used in this study, Emblica officinalis (Nelli / Amla) and  Tinospora cordifolia  (Rasakinda / Guduchi) preventedcancer recurrence of tongue and buccal mucosa cancer during a 5 year follow up period, which led to an overall improvement in the survival rate. And in conclusion pharmaceutical or medicinal preparation comprising a combination of two herbs  Emblica officinalis 
 (Nelli)  and  Tinospora cordifolia (Rasakinda ) can be administered together for targeted stimulation of immune system for prophylaxis and treatment of oral cancer.
Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
The shaving stick is a means of dispensing shaving lubricant directly onto the skin without the need of other tools. The saving stick is the combination of a shaving lubricant and an applicator assembly; whereby, the shaving lubricant may be any formulation of shaving soap, cream, gel, lotion, or liquid. As such, users of our invention, the shaving stick, may apply the shaving aid directly to the face, legs, under arms, etc. without the use their hands, as is needed with shaving creams, astringents, and other lubricants on the market. Current embodiments of our invention resemble visually and functionally the various underarm deodorants available in the market today. By replacing the deodorant with a shaving lubricant, the shaving stick overcomes the many inconveniences associated with current shaving aids.
PROBLEM TO BE SOLVED: To obtain the subject composition that is excellent in resistance to oil separation, moist feeling, cream spreadability, in addition, cosmetic applicability and resistance to make-up collapse, when it is used as cosmetic primer, by formulating specific amino acids and/or saccharides to borage oil. SOLUTION: The objective composition is obtained by formulating (A) amino acids, preferably glycine or arginine and/or (B) saccharides preferably sorbitol or trehalose to borage oil that is extracted from borage grass and contains γ-linolenic acid. The amount of the component A is 0.01-10 pts.wt. per 100 pts.wt. of the borage oil, while the weight ratio of the component A to the component B is 1/2-5/1, when they are used in combination. The effect of this composition is markedly revealed, when lecithin (as soybean lecithin) is formulated in an amount of 0.1-30 pts.wt. per 100 pts.wt. of the borage oil.